Tiziana Life Sciences plc Change to ADS Ratio - Updated
July 15, 2020 11:55 ET
|
Tiziana Life Sciences Plc
NEW YORK and LONDON, July 15, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc ("Tiziana", AIM: TILS, NASDAQ: TLSA), announces a ratio change to its sponsored Level 3 American Depositary Receipt...
Tiziana Life Sciences plc Change to ADS Ratio
July 15, 2020 08:28 ET
|
Tiziana Life Sciences Plc
NEW YORK and LONDON, July 15, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc ("Tiziana", AIM: TILS, NASDAQ: TLSA), announces a ratio change to its sponsored Level 3 American Depositary Receipt...
Tiziana Life Sciences Interview to Air on Bloomberg International on the RedChip Money Report
July 10, 2020 13:41 ET
|
Tiziana Life Sciences Plc
NEW YORK and LONDON, July 10, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a clinical stage biotechnology company developing targeted...
Tiziana Life Sciences Announces Agreement with STC Biologics for GMP Manufacturing of an anti-Interleukin-6-Receptor Monoclonal Antibody for Clinical Studies in Patients with COVID-19
June 29, 2020 03:12 ET
|
Tiziana Life Sciences PLC
NEW YORK and LONDON, June 29, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a clinical stage biotechnology company developing targeted...
Tiziana Granted First-Ever Patent on a Transformational Technology for Oral Delivery of all Anti-CD3 Monoclonal Antibodies for Treatment of Human Diseases
June 19, 2020 02:00 ET
|
Tiziana Life Sciences PLC
First-ever granted patent on oral administration of anti-CD3 monoclonal antibodies for immunotherapiesTransformational oral formulation technologies applicable to other antibodies This announcement...
Tiziana Life Sciences PLC Directorate Change
June 18, 2020 13:50 ET
|
Tiziana Life Sciences Plc
LONDON and NEW YORK, June 18, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA / AIM: TILS) ("Tiziana" or the "Company"), the U.S. and U.K. biotechnology company that focuses on the...
Tiziana Life Sciences announces that its Scientific Advisory Board Chairman Dr. Howard Weiner received NIH grant to investigate Nasal Anti-CD3 for the treatment of Alzheimer’s disease
June 04, 2020 02:00 ET
|
Tiziana Life Sciences PLC
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. NEW YORK and LONDON, June 04, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA...
Tiziana Life Sciences announces presentation of StemPrintER, a superior prognostic test as compared to Oncotype DX to predict breast cancer
May 29, 2020 02:00 ET
|
Tiziana Life Sciences PLC
StemPrintER Outperforms Oncotype DX in analysis with 800+ samples from ER+/HER2- postmenopausal breast cancer patientsSPARE Model is up to 40-50% more accurate than standard clinical markers in...
Tiziana Lifesciences Announces Intention to Demerge Its StemPrintER Genomics-Based Personalized Medicine Business as a Separate Listed Company
May 22, 2020 02:00 ET
|
Tiziana Life Sciences PLC
NEW YORK and LONDON, May 22, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, AIM: TILS), a clinical stage biotechnology company developing targeted drugs for cancer, inflammatory...
Tiziana Lifesciences Announces Online Publication of Two Abstracts at the American Society of Clinical Oncology (ASCO) Reporting Clinical Activity and Safety of Milciclib in Patients with Advanced Hepatocellular Carcinoma
May 14, 2020 10:00 ET
|
Tiziana Life Sciences PLC
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. NEW YORK and LONDON, May 14, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA,...